Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib effect on growth and signal transduction in polycythemia vera.

Experimental hematology - 1 Jun 2007

Gaikwad Amos, Verstovsek Srdan, Yoon Donghoon, Chang Ko-Tung, Manshouri Taghi, Nussenzveig Roberto, Cortes Jorge, Vainchenker William, Prchal Josef T

Abstract excerpt

OBJECTIVE: An activating mutation of Janus kinase 2 (JAK2) in majority of polycythemia vera (PV) and other myeloproliferative disorders was reported. As imatinib inhibits several tyrosine kinases, we studied its effect in PV. PATIENTS AND METHODS: We employed FDCP reporter cells expressing wild-type JAK2 and mutant JAK2(V617F) to study the efficacy of imatinib by cell proliferation assay and its effect on several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imatinib Mesylate
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Erythroid Precursor Cells

Share to Granulocytes

Share to Piperazines

Share to Polycythemia Vera

Share to STAT5 Transcription Factor

Source

Identifiers

PMID: 17533047
DOI: 10.1016/j.exphem.2007.03.012

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Imatinib effect on growth and signal transduction in polycythemia vera.PMID 17533047Read ↗

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alphaSemantic proximity Read ↗

Mutated JAK2 signal transduction in human induced pluripotent stem cell (iPSC)-derived megakaryocytes.Semantic proximity Read ↗

Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell GrowthSemantic proximity Read ↗

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.Semantic proximity Read ↗

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.Semantic proximity Read ↗

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.Semantic proximity Read ↗

Differential Sensitivity to JAK Inhibitory Drugs by Isogenic Human Erythroblasts and Hematopoietic Progenitors Generated from Patient-Specific Induced Pluripotent Stem CellsSemantic proximity Read ↗

Inhibitory effect of imatinib on normal progenitor cells in vitroSemantic proximity Read ↗

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell linesSemantic proximity Read ↗

Comparison of two homogeneous cell-based kinase assays for JAK2 V617F: SureFire pSTAT5 and GeneBLAzer fluorescence resonance energy transfer assays.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.